Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Lenacapavir, an innovative twice-yearly injection that prevents HIV transmission, was recognized as the breakthrough medicine ...

Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.

Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...